Queensland Institute of Medical Research
12
2
2
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
8.3%
1 terminated/withdrawn out of 12 trials
88.9%
+2.4% vs industry average
17%
2 trials in Phase 3/4
25%
2 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Eating Disorders Genetics Initiative 2
Role: collaborator
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
Role: lead
Linking Obesity and Estrogen-responsive Genes in Endometrial Cancer
Role: collaborator
A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection
Role: collaborator
Inoculating Celiac Disease Patients With the Human Hookworm Necator Americanus: Evaluating Immunity and Gluten-sensitivity
Role: collaborator
Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers
Role: collaborator
Monitoring the Efficacy of Anthelmintics for the Treatment of Soil Transmitted Helminths P2
Role: collaborator
Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer
Role: collaborator
Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas
Role: lead
A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in Children
Role: collaborator
A Pilot Study to Test Activity of Antimalarial Drugs Against an Induced Malaria Infection in Healthy Volunteers
Role: collaborator
The Prevalence of Rheumatic Heart Disease in School Children in Fiji
Role: lead
All 12 trials loaded